Related Experiment Video
Updated: Aug 24, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Trial of targeting therapy against malignant glioma using monoclonal antibody
Hiroshi Takahashi1, Akira Teramoto
1Department of Neurosurgery, Nippon Medical School.
Abstract:
Although the conventional treatment of malignant gliomas including surgery, radiotherapy and systemic chemotherapy has advanced, their current prognosis remains poor. The reactivity of monoclonal antibodies (mAbs) with human tumor cells may allow precise localization and appropriate therapy. We have developed several mAbs against malignant gliomas, and have reported the results of the experimental studies aimed at their clinical application as targeting therapy. The initial results of employing murine mAb 425 which binds to specifically to the epidermal growth factor (EGF) receptor in glioma therapy have been excellent, but less satisfactory, positively due to the immunogenicity of the murine mAbs, and limitations of the efficacy of the unmodified antibodies. Therefore, we also investigated the accumulation and the tumor suppression effect of human mAb CLNIgG and CLNIgG-drug (DXR: doxorubicin) conjugates to the tumor. The human mAb CLNIgG, derived from human uterine cancer lymph node cells, was found to bind strongly to human malignant glioma cells.
Insights
Researchers developed human monoclonal antibodies (mAbs) for targeted malignant glioma therapy. Human mAb CLNIgG shows strong binding to glioma cells, offering a promising alternative to murine mAbs for improved treatment efficacy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Malignant gliomas have a poor prognosis despite advances in conventional treatments.
- Monoclonal antibodies (mAbs) offer potential for precise tumor localization and targeted therapy.
- Murine mAbs have shown promise but face limitations like immunogenicity and efficacy.
Purpose of the Study:
- To develop and evaluate human monoclonal antibodies for targeted malignant glioma therapy.
- To investigate the efficacy and tumor-binding properties of human mAb CLNIgG and its drug conjugate.
- To overcome the limitations associated with murine mAbs in glioma treatment.
Main Methods:
- Development of several monoclonal antibodies against malignant gliomas.
- Experimental studies on the clinical application of mAbs for targeting therapy.
- Investigation of human mAb CLNIgG and CLNIgG-doxorubicin conjugate accumulation and tumor suppression effects.
Main Results:
- Human mAb CLNIgG demonstrates strong binding affinity to human malignant glioma cells.
- Murine mAb 425 showed initial promise but was limited by immunogenicity and efficacy.
- Human mAb CLNIgG offers a potentially safer and more effective alternative for glioma targeting.
Conclusions:
- Human mAb CLNIgG is a viable candidate for targeted malignant glioma therapy.
- Development of human mAbs represents a significant advancement over murine mAbs for glioma treatment.
- Further research into CLNIgG-drug conjugates may enhance therapeutic outcomes for malignant gliomas.
